Clinical Trials Directory

Trials / Conditions / Stage IV Uterine Corpus Cancer AJCC v7

Stage IV Uterine Corpus Cancer AJCC v7

11 registered clinical trials studyying Stage IV Uterine Corpus Cancer AJCC v7 — 1 currently recruiting.

StatusTrialSponsorPhase
RecruitingCollecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069
Alliance for Clinical Trials in Oncology—
Active Not RecruitingVSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer
NCT03120624
Mayo ClinicPhase 1
CompletedEnzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid End
NCT02684227
M.D. Anderson Cancer CenterPhase 2
WithdrawnWeb-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With
NCT03902379
Rutgers, The State University of New JerseyN/A
Active Not RecruitingmTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
NCT02208375
M.D. Anderson Cancer CenterPhase 1
Active Not RecruitingSurgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopi
NCT01970722
City of Hope Medical CenterPhase 1
UnknownPaclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or
NCT02065687
Gynecologic Oncology GroupPhase 2 / Phase 3
CompletedDasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
NCT01440998
National Cancer Institute (NCI)Phase 1
CompletedEribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tum
NCT00410553
National Cancer Institute (NCI)Phase 1
UnknownFulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer
NCT00006903
Gynecologic Oncology GroupPhase 2
CompletedTrastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
NCT00006089
National Cancer Institute (NCI)Phase 2